Bevacizumab for ophthalmic diseases

被引：2
|
作者：
Michels, Stephan [1 ]
Prager, Franz [1 ]
Bakri, Sophie J. [2 ]
Wacht, Joachim [3 ]
机构：
[1] Med Univ Vienna, Gen Hosp Vienna, Dept Ophthalmol, Wahringer Gurtel 18-20, Vienna, Wien 1090, Austria
[2] Dept Ophthalmol, Rochester, MN 55905 USA
[3] Dept Ophthalmol, Berlin, Germany
来源：
EXPERT REVIEW OF OPHTHALMOLOGY | 2007年 / 2卷 / 03期
关键词：
AMD; angiogenesis; anti-VEGF; Avastin ((R)); bevacizumab; choroidal neovascularization; eye; macular degeneration; neovascularization; ocular; vascular endothelial growth factor;
D O I：
10.1586/17469899.2.3.369
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
Bevacizumab, a humanized monoclonal antibody that binds to all isoforms of vascular endothelial growth factor, was originally developed to inhibit tumor angiogenesis. Following its approval for the treatment of metastatic colorectal cancer, bevacizumab was initially used systemically in patients with neovascular age-related macular degeneration. Two case reports on intravitreal bevacizumab led to numerous clinical and preclinical studies on bevacizumab. Intravitreal bevacizumab is popular worldwide as an inexpensive off-label treatment for several neovascular ocular diseases. This article reviews the current clinical and preclinical studies using bevacizumab in ophthalmology.
引用
收藏
页码：369 / 378
页数：10
相关论文
共 50 条
  • [21] Cellular senescence and ophthalmic diseases: narrative review
    Mohammad Soleimani
    Kasra Cheraqpour
    Raghuram Koganti
    Ali R. Djalilian
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2023, 261 : 3067 - 3082
  • [22] Induction of vascular endothelial growth factor receptor expression in human umbilical vein endothelial cells after repeated bevacizumab treatment in vitro
    Lee, Ji Eun
    Kim, Jin Young
    Jung, Jae Ho
    Shin, Dong Hoon
    Park, Sung Who
    INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2017, 10 (07) : 1064 - 1068
  • [23] Demography and age-dependency in ophthalmic diseases
    Wolfram, C.
    OPHTHALMOLOGE, 2015, 112 (01): : 73 - 80
  • [24] Angiogenesis and ophthalmic disease
    Adamis A.P.
    Aiello L.P.
    D'Amato R.A.
    Angiogenesis, 1999, 3 (1) : 9 - 14
  • [25] Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization?
    Lu, Fang
    Adelman, Ron A.
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2009, 247 (02) : 171 - 177
  • [26] Effects of Subconjunctival Bevacizumab on Corneal Neovascularization: Results of a Prospective Study
    Benayoun, Yohan
    Adenis, Jean-Paul
    Casse, Guillaume
    Forte, Raimondo
    Robert, Pierre-Yves
    CORNEA, 2012, 31 (08) : 937 - 944
  • [27] Intravitreal bevacizumab for pediatric exudative retinal diseases
    Salman, Abdelrahman G.
    SAUDI JOURNAL OF OPHTHALMOLOGY, 2011, 25 (02) : 193 - 197
  • [28] Bevacizumab for ocular neovascular diseases: a systematic review
    Andriolo, Regis Bruni
    Puga, Maria Eduarda
    Belfort Junior, Rubens
    Atallah, Alvaro Nagib
    SAO PAULO MEDICAL JOURNAL, 2009, 127 (02): : 84 - 91
  • [29] Anti-vascular endothelial growth factor drugs safety and efficacy in ophthalmic diseases
    Ventrice, Pasquale
    Leporini, Christian
    Aloe, Jose' Francisco
    Greco, Ettore
    Leuzzi, Giacomo
    Marrazzo, Giuseppina
    Scorcia, Giovanni Battista
    Bruzzichesi, Donatella
    Nicola, Varano
    Scorcia, Vincenzo
    JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS, 2013, 4 (05) : S38 - S42
  • [30] Bevacizumab and ovarian cancer
    Sato, Shinya
    Itamochi, Hiroaki
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2012, 24 (01) : 8 - 13
12345